AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9 th – 11 th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9 th and 10 th .
H.C. Wainwright 26th Annual Global Investment Conference: September 9 th – 11 th
| Title: | Lumos Pharma Corporate Presentation (On-Demand) | |
| Date/Time: | September 9 th at 7:00AM EDT | |
| Webcast Link: | Register here | |
| 1x1 Meetings: | Monday-Tuesday, September 9 th -10 th | |
The presentation webcast can be downloaded at 7:00AM EDT on September 9 th and will be available for 90 days thereafter. The webcast can also be accessed on the Company’s website under Events & Presentations in the Investors & Media section. Please contact your H.C. Wainwright salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with management at the conference or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/ .
Investor & Media Contact:
Lisa Miller Lumos Pharma Investor Relations 512-792-5454 ir@lumos-pharma.com
